Navigation Links
Novexel Presents 16 Posters and one Slide Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting in San Francisco
Date:9/11/2009

p> Novexel is a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the global hospital antibiotic market, which was worth an estimated $17bn in 2008.[1]

Novexel currently has two novel antibacterials in Phase II clinical development. These are the injectable beta-lactamase inhibitor, NXL104, which is being developed in combination with the cephalosporin antibiotic ceftazidime for serious Gram negative infections, and the oral streptogramin antibiotic, NXL103, for the treatment of Gram positive infections, with a focus on treatment in the hospital setting and intravenous (IV) to oral switch. Novexel has three further programmes in preclinical development, NXL105, a novel anti-Pseudomonal antibiotic, NXL201, a novel echinocandin antifungal agent, and NXL104 in combination with ceftaroline. This latter product is being developed by Novexel's partner, Forest Laboratories (NYSE: FRX), solely for North American markets.

Novexel was created in December 2004 as an independent spin-out of the sanofi-aventis (Euronext Paris: SAN, NYSE: SNY) anti-infectives unit. Novexel has a team of 50 employees with significant experience in anti-infective research and development, who are located in Paris, France and Philadelphia, USA.

    [1] Source: IMS Health, MIDAS, 2006-2008

    For further information please contact:

    Novexel
    Gordon Waldron, CFO
    Tel: +33-1-5714-0
'/>"/>
SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Novexel Strengthens its Scientific Advisory Board With the Appointment of Dr. Karen Bush
2. Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
3. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
4. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
5. iSEEK Enterprise Presents Collaboration with Penn Medicine at 2009 AMEE Conference
6. Viral Genetics Scientist Presents Potential New Treatment for Drug Resistant Brain Tumors at Aspen Symposium
7. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
8. Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
9. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
10. Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
11. Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Controlled Substance Compliance Services ... helps companies check the legal requirements around using controlled ... China. , As their international operations expand and ... software solutions built as a result of the first ...
(Date:1/22/2015)... ALTO, Calif. , Jan. 22. 2015  Varian Medical Systems ... and software, has been honored for its commitment to sustainability ... sustainable companies. Varian is the highest ranked healthcare equipment company ... announced today during the World Economic Forum at ...
(Date:12/24/2014)... and NEW YORK , Dec. 24, 2014 ... advancing patient care in critical areas, announced the closing of ... and warrants to purchase up to an aggregate 3,500,000 shares ... share and $.01 per warrant.  The warrants have a per ...
(Date:12/24/2014)... Earlier this year in a June 24 international ... Stem Cell Technology Center, LLC ( ASCTC ) focused attention ... adult tissue stem cells. His title “Asymmetric Self-Renewal by ... Future,” embodied the essence of his message to congress participants. ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... April 3, 2008 Alba Therapeutics Corporation,today announced ... Chief Executive,Officer (CEO) and a member of its ... with SV Life Sciences Advisors, LLC. Previously, he ... the senior management team for several,successful entrepreneurial healthcare ...
... A policy comment in Science,today quotes Genelex out ... claims about the utility of CYP450,testing for particular ... testing is "required to effectively prescribe Paxil",( http://www.healthanddna.com/professional/paxil.html ... (paroxetine) is metabolized through CYP2D6. Pharmacogenetic,testing of this ...
... Term Development Agreement to Produce Reference Standard Reagents to ... ... 2008 Strategic,Diagnostics Inc. (Nasdaq: SDIX ) -- a ... sciences industry announced that it has,been selected by Science Applications ...
Cached Biology Technology:Alba Therapeutics Announces Appointment of Bruce A. Peacock as its Chief Executive Officer 2Science Fuels DNA Testing Controversy with Prejudicial Misquote 2Strategic Diagnostics Inc. Selected as Key Supplier to SAIC-F and the National Cancer Institute for the Development of a Comprehensive Portfolio of Antibodies for Use in Cancer Research 2Strategic Diagnostics Inc. Selected as Key Supplier to SAIC-F and the National Cancer Institute for the Development of a Comprehensive Portfolio of Antibodies for Use in Cancer Research 3
(Date:12/10/2014)... NEW YORK , Dec. 8, 2014 You,ve been here ... but can,t remember your password, site key or the answer to ... grade teacher? Today, Hoyos Labs , a ... finally put an end to the frustration that comes with usernames, ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Wake Forest Baptist Medical ... for its School of Medicine. Funding for this $50 million ... will be publicly launched next summer. The ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in ...
(Date:12/10/2014)... Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ) has announced the ... report to their offering. ... and smart cards for projects such as rural banking ... the major trends witnessed in the market. Besides the ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... WI, NOVEMBER 17, 2008 Global land use patterns ... urban stormwater management. Traditional stormwater management focuses on ... generally does little to restore the hydrologic cycle ... with low permeability. The lack of infiltration opportunities ...
... Mellon University,s Robotics Institute have received a total of ... Agriculture (USDA) to build automated farming systems. One is ... but both are designed to improve fruit quality and ... autonomous robotic vehicles or at fixed sites within the ...
... team of researchers led by investigators at the Albert ... that certain commonly-prescribed medications may have the unintended consequence ... finding could alter the way doctors prescribe migraine medicines. ... Headache , the Einstein-led study of more than ...
Cached Biology News:Urban trees enhance water infiltration 2Carnegie Mellon developing automated systems to enable precision farming of apples, oranges 2Carnegie Mellon developing automated systems to enable precision farming of apples, oranges 3Overuse of narcotics and barbiturates may make migraine worse 2
Phospho-4E-BP1 (Thr37/46) (236B4) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
Goat polyclonal to FBXO2 ( Abpromise for all tested applications). entrezGeneID: 26232 SwissProtID: Q9UK22...
Anti-Dardarin Immunogen: Synthetic peptide from rat LRRK2. Available Date: 38814...
Gamma delta T Lymphocytes Purified Anti-Porcine clone MAC320, Isotype Rat IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Biology Products: